MétaCan
Menu
Back to cohort
Record W4388343130 · doi:10.1016/j.ctarc.2023.100774

Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence

2023· article· en· W4388343130 on OpenAlexafffund
Niki Esfahanian, Sze Wah Samuel Chan, Luna Jia Zhan, M. Catherine Brown, Khaleeq Khan, Jae Lee, Karmugi Balaratnam, Elizabeth Yan, Jennifer J. Parker, Miguel García-Pardo, Samir H. Barghout, Lawson Eng, Penelope A. Bradbury, Frances A. Shepherd, Natasha B. Leighl, Adrian G. Sacher, Stephanie Snow, Rosalyn A. Juergens, Geoffrey Liu

Bibliographic record

VenueCancer Treatment and Research Communications · 2023
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsJuravinski Cancer CentrePrincess Margaret Cancer CentreMcMaster UniversityDalhousie UniversityUniversity of TorontoUniversity Health Network
FundersAmgen Canada
KeywordsMedicineHazard ratioInternal medicineStage (stratigraphy)OncologyTargeted therapyProgressive diseaseLung cancerCancerDiseaseGastroenterologyConfidence interval

Abstract

fetched live from OpenAlex

• Patients with metastatic KRAS G12C -mutated NSCLC have few therapy options. • Patients who develop metastasis at recurrence may have better performance than patients with initial metastatic disease ( de novo ). • We found that de novo patients had more disease and were less fit for therapy compared to recurrent patients. • There is an urgent need for targeted therapy for patients with de novo KRAS G12C –mutated NSCLCs. Close monitoring after diagnosis of patients with stage I-III non-small cell lung cancer (NSCLC) may result in fitter patients with lower disease burden at the time of metastatic recurrence or progression compared to patients diagnosed initially as stage IV ( de novo ). We compared the presentation, treatments, and outcomes of patients with KRAS G12C -mutated NSCLC with de novo versus recurrent stage IV disease. Of 109 patients, 94% had a smoking history. When compared to patients with KRAS G12C -mutated NSCLC who developed stage IV disease at recurrence ( n = 38), de novo s tage IV patients ( n = 71) had worse ECOG performance status ( p = 0.007), greater numbers of extra-thoracic metastatic sites ( p = 0.001), and were less likely to receive 2nd/3rd line systemic therapy ( p = 0.05, p = 0.002) or targeted therapy ( p = 0.001). De novo metastatic patients had shorter overall survival than metastatic patients at recurrence (9.1 versus 24.2 months; adjusted-hazard-ratio=1.94 (95% CI: 1.14–3.28; p = 0.01)). There is a critical need for well-tolerated targeted therapies in the first-line setting for metastatic patients with de novo , high-burden, stage IV KRAS G12C -mutated NSCLCs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.060
Threshold uncertainty score0.472

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.078
GPT teacher head0.443
Teacher spread0.365 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueCancer Treatment and Research CommunicationsSame topicLung Cancer Treatments and MutationsFrench-language works237,207